Management Change/Compensation (Form 8-K)

On February 9, 2026, the Board of Directors of Cue Biopharma, Inc. (the "Company") appointed Lucinda Warren, the Chief Business Officer of the Company, as Chief Financial and Business Officer of the Company, effective February 9, 2026. Upon commencement of her appointment, Ms. Warren assumed the duties of the Company's principal financial officer and principal accounting officer. Ms. Warren has served as Chief Business Officer of the Company since September 2024.

Ms. Warren, age 57, has over 30 years of global experience in the pharmaceutical and biotechnology sectors. Prior to joining the Company, she served as vice president of business development for Neuroscience and Japan Regionally at Johnson & Johnson, a healthcare products company, from 2014 to 2024, where she was responsible for end-to-end business development, including licensing, mergers and acquisitions, and alliance management. Ms. Warren previously held significant roles at Janssen Cilag Australia and Janssen Biologics, where she led business units and managed global transitions. She currently serves as chairman of the board of International School Services. Ms. Warren holds a B.S. in biological sciences with a minor in neurology from the University of Alberta.

Ms. Warren will not receive any additional compensation for assuming these roles, and no material changes will be made to her employment agreement in connection with this appointment. Ms. Warren will continue to participate in the benefits and other Company plans and arrangements in which she currently participates.

There are no arrangements or understandings between Ms. Warren and any other persons pursuant to which Ms. Warren was appointed as Chief Financial and Business Officer. There are no family relationships between Ms. Warren and any director or executive officer of the Company, and there are no transactions between Ms. Warren and the Company that would be reportable under Item 404(a) of Regulation S-K.